HealthTech180
  • Home
  • Activities
  • Our Team
  • Contact Us
Select Page

Dragonfly Therapeutics Initiates Phase 1/2 Study of DF1001 in Patients with Advanced Solid Tumors

by admin | Nov 18, 2019 | Clinical Trials

Dragonfly Therapeutics, a biotechnology company developing novel immunotherapies that harness the innate immune system to treat disease, announced that the first patient was dosed in a Phase 1/2 study of DF1001 at The University of Texas MD Anderson Cancer Center in...
Follow Us
We are a one-stop shop Healthcare Advisory & Consulting boutique and we help businesses with funding, market access, business strategy, distribution.

Categories

Follow Us

Tags

AI Alzheimer antibodies Azitra Bioeq Biosimilar Cancer cardiovascular cell therapy CE Mark clinical trial Diagnostics Digital Health Distribution Drug Discovery Enterome EpiVax' FDA FDA approval funding fundraising HIV Immunogenicity Immunotherapies Licensing M&A medical device microbiome Neuro next-gen sequencing PathAI pathology Pepticom pharma RNA robots Shape Therapeutics skin software SurgiMab Therapeutics therapies USA VIrology Virus

Home
Activities
Our Team
Contact Us

 contact@healthtech180.com

Privacy Policy

© 2022 HealthTech180 Advisory S.L.